Jim founded Delphi Ventures in 1988. His focus is on medical devices and biotechnology.

Jim began investing in medical companies in 1981 after co-founding Technology Venture Investors, a private venture capital partnership. Since 1984, he has focused exclusively on healthcare investments.

From 1976 to 1980, Jim was with Shugart Associates, a venture-backed disk drive company. As President and CEO, he led Shugart to increasing profitability, with annual revenues growing from $13 million to $200 million. Shugart was acquired by Xerox in 1979.

From 1972 to 1976, Jim was a general partner with Donaldson Lufkin & Jenrette's (DLJ) venture capital arm, the Sprout Capital Group. Prior to that, he served as a securities analyst with DLJ.

Trained as an aerospace engineer at MIT, Jim served as an Army officer and a missile systems engineer with the U.S. Army Missile Intelligence Directorate, serves on the Board of Overseers of the Hoover Institution at Stanford University and is a member of the Harvard School of Public Health’s Health Policy and Management Executive Council. Jim was a director of the Western Association of Venture Capital.

EDUCATION

• MBA with Distinction, Harvard University Graduate School of Business
• BS Massachusetts Institute of Technology

REPRESENTATIVE BOARD INVOLVEMENT

• Applied Molecular Evolution, Inc., (AMEV) a.b. Eli Lilly & Co. (LLY)
• ArKal Medical, Inc.
• Ascent Healthcare Solutions, Inc. (formerly Alliance Medical, Inc.)
• Avicenna Systems Corp., a.b. WebMD Corp. (HLTH)
• CollaGenex Pharmaecuticals, Inc. (CGPI)
• Exogen, Inc. (EXGN) a.b. Smith & Nephew, Inc. (SNS)
• ImmuLogic Pharmaceuticals, Inc. (IMUL)
• Integrated Vascular Systems, Inc. a.b. Abbott Laboratories (ABT)
• Micro Interventional Systems, Inc. a.b. Medtronic, Inc. (MDT)
• MicroVention, Inc. a.b. Terumo Corporation
• Natus Medical, Inc. (BABY)
• PixelOptics, Inc.
• PhotoThera, Inc.
• Synaptics, Inc. (SYNA)
• SynergEyes, Inc.
• Vital Therapies, Inc.